Fundamental Analysis of PROTHENA CORP PLC(NASDAQ:PRTA) stock

Fundamental Rating

Overall PRTA gets a fundamental rating of 4 out of 10. We evaluated PRTA against 564 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PRTA as it has an excellent financial health rating, but there are worries on the profitability. PRTA is valued quite expensively, but it does show have an excellent growth rating.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PRTA has reported negative net income.

PRTA had a negative operating cash flow in the past year.

In the past 5 years PRTA reported 4 times negative net income.

In the past 5 years PRTA reported 4 times negative operating cash flow.

1.2 Ratios

PRTA has a better Return On Assets (-7.89%) than 89.48% of its industry peers.

PRTA has a better Return On Equity (-8.75%) than 91.27% of its industry peers.

		Industry Rank	Sector Rank
ROA	-7.89%
ROE	-8.75%
ROIC	N/A

ROA(3y)-8.51%

ROA(5y)-15.49%

ROE(3y)-10.2%

ROE(5y)-23.89%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PRTA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PRTA does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, PRTA has more shares outstanding

The number of shares outstanding for PRTA has been increased compared to 5 years ago.

There is no outstanding debt for PRTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

PRTA has an Altman-Z score of 7.18. This indicates that PRTA is financially healthy and has little risk of bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 7.18, PRTA belongs to the top of the industry, outperforming 81.11% of the companies in the same industry.

There is no outstanding debt for PRTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	7.18

ROIC/WACCN/A

WACC7.19%

2.3 Liquidity

A Current Ratio of 12.54 indicates that PRTA has no problem at all paying its short term obligations.

The Current ratio of PRTA (12.54) is better than 84.85% of its industry peers.

PRTA has a Quick Ratio of 12.54. This indicates that PRTA is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of PRTA (12.54) is better than 84.85% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	12.54
Quick Ratio	12.54

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.90% over the past year.

PRTA shows a strong growth in Revenue. In the last year, the Revenue has grown by 277.22%.

The Revenue has been growing by 146.70% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)63.9%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%218.45%

Revenue 1Y (TTM)277.22%

Revenue growth 3Y366.5%

Revenue growth 5Y146.7%

Sales Q2Q%3184.75%

3.2 Future

The Earnings Per Share is expected to grow by 29.53% on average over the next years. This is a very strong growth

Based on estimates for the next years, PRTA will show a very strong growth in Revenue. The Revenue will grow by 54.21% on average per year.

EPS Next Y15.02%

EPS Next 2Y-25.16%

EPS Next 3Y6.34%

EPS Next 5Y29.53%

Revenue Next Year60.28%

Revenue Next 2Y-0.83%

Revenue Next 3Y35.87%

Revenue Next 5Y54.21%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRTA. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRTA. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-25.16%

EPS Next 3Y6.34%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PRTA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PROTHENA CORP PLC

NASDAQ:PRTA (11/4/2024, 8:00:00 PM)

After market: 16.46 0 (0%)

16.46

-0.19 (-1.14%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap885.22M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-7.89%
ROE	-8.75%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.34

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	12.54
Quick Ratio	12.54
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)63.9%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y15.02%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)277.22%

Revenue growth 3Y366.5%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PROTHENA CORP PLC (PRTA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens